Hydroxyl purine compounds and applications thereof
AssigneeGuangdong Raynovent Biotech Co., Ltd.
InventorsLingyun Wu, Chaofeng Long, Peng Zhang, Xiaoxin Chen, Li Zhang, Zhuowei Liu, Jian Li, Shuhui Chen
Life of this patent
Estimating the term…
Abstract
Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-α inhibitors.
Claims22
A compound having a structure of formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof,
- wherein,
- the structural unit
- can be replaced with
- L11 is selected from absence, or C(R)(R′);
- each of R and R′ is independently selected from H, a halogen, OH, NH2, CN, or an optionally substituted 1- to 6-membered alkyl or heteroalkyl;
- or, R and R′ to join together and form a 3- to 6-membered cycloalkyl or heterocycloalkyl including the carbon of L11 by cyclization;
- A is selected from
- L12 is selected from methylene,
- R1 is selected from an optionally substituted 1- to 6-membered alkyl or heteroalkyl;
- “hetero” represents N, O, S, C(═O), S(═O), or S(═O)2, the number of the heteroatom on each group is selected from 1, 2, 3 or 4.
A compound selected from the group consisting of:
A compound selected from the group consisting of:
A method for inhibiting PDE2 and TNF-α in a subject in need thereof, comprising:
- administering to the subject an effective amount of a compound having a structure of formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof,
- wherein,
- the structural unit
- can be replaced with
- L11 is selected from absence, or C(R)(R′),;
- each of R and R′ is independently selected from H, a halogen, OH, NH2, CN, or an optionally substituted 1- to 6-membered alkyl or heteroalkyl;
- or, R and R′ to join together and form a 3- to 6-membered cycloalkyl or heterocycloalkyl including the carbon of L11 by cyclization;
- A is selected from cyclopropyl, cyclopentyl, cyclohexyl, epoxypentyl, phenyl, pyridyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, or bicyclor[1.1.11]pentane bicyclo[1.1.1]pentane, or a bicyclic group, a spiro group or a fused cyclic group consisting of any two of the above groups, each of which is optionally substituted;
- L12 is selected from an optionally substituted 1- to 6-membered alkyl or heteroalkyl;
- R1 is selected from an optionally substituted 1- to 6-membered alkyl or heteroalkyl;
- “hetero” represents N, O, S, C(═O), S(═O), or S(═O)2, the number of the heteroatom on each group is selected from 1, 2, 3 or 4.
A compound having a structure of formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof,
- wherein,
- the structural unit
- can be replaced with
- L11 is selected from absence, or C(R)(R′);
- each of R and R′ is independently selected from H, a halogen, OH, NH2, CN, or an optionally substituted 1- to 6-membered alkyl or heteroalkyl;
- or, R and R′ join together and form a 3- to 6-membered cycloalkyl or heterocycloalkyl including the carbon of L11 by cyclization;
- A is selected from cyclopropyl, cyclopentyl, cyclohexyl, epoxypentyl, pyridyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, or bicyclo[1.1.1]pentane, each of which is optionally substituted;
- L12 is selected from methylene,
- R1 is selected from an optionally substituted 1- to 6-membered alkyl or heteroalkyl;
- “hetero” represents N, O, S, C(═O), S(═O), or S(═O)2, the number of the heteroatom on each group is selected from 1, 2, 3 or 4,
- the substituents in the R, R′, A and R1 are independently selected from a halogen, OH, NH2, CN, CF3,
- or 1- to 6-membered alkyl and heteroalkyl, the number of the substituent on each group is independently selected from 1, 2 or 3.
Dependencies are inferred from the claim text.